Evidence map›Paper›PMID 41971680›Full record

ArticleFrontiers in molecular biosciences2026

Comparative analysis of tissue-specific anticancer peptide prediction models: ACP-Boost framework.

Ruizhe Kang, Weichen Yuan, Mingjun Tang, Hongguang Zhou

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruizhe KangDepartment of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Weichen YuanDepartment of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Mingjun TangDepartment of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Hongguang ZhouDepartment of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a major global health burden, and conventional treatments such as surgery, radiotherapy, and chemotherapy are often limited by systemic toxicity, drug resistance, and high cost. Anticancer peptides (ACPs) have emerged as promising therapeutic candidates because of their selective activity against tumor cells; however, experimental identification of ACPs is labor-intensive and time-consuming, and peptide activity may vary across tissue contexts. Although many computational models have been developed for general ACP prediction, tissue-specific ACP classification remains insufficiently explored. In this study, we developed ACP-Boost, a tissue-aware machine learning framework for tissue-specific ACP classification across nine cancer-related tissues: blood, brain, breast, cervix, colon, liver, lung, prostate, and skin. Experimentally validated peptide records were integrated from CancerPPD2 and DCTPep, followed by preprocessing, redundancy control, and tissue annotation. Peptide sequences were encoded into 473-dimensional feature vectors comprising amino acid composition (AAC), dipeptide composition (DPC), physicochemical property composition (PCP), and pseudo-amino acid composition (PseAAC). To address class imbalance while preserving the original sequence distribution, we formulated the task as a one-versus-rest classification problem, applied group-aware train-test splitting based on peptide sequences, and emphasized evaluation metrics suitable for imbalanced data. We systematically compared five machine learning algorithms, including support vector machine, random forest, logistic regression, k-nearest neighbors, and XGBoost. Among them, XGBoost showed the most stable overall performance across tissues. The results indicate that peptide sequence-derived descriptors contain measurable tissue-associated signals, although predictive separability remains moderate for several cancer types. Feature importance analysis further suggested that both shared charge-related properties and tissue-dependent sequence descriptors contribute to model discrimination. Overall, this study provides a comparative computational framework for tissue-specific ACP classification and highlights the importance of incorporating biological heterogeneity into peptide prediction tasks.

Indexed as

anticancer peptidescancer therapeuticsdataset constructiondipeptide compositionfeature encodingsmachine learningtissue-specific classificationXGBoost

Identifiers

PMID41971680
PMCPMC13062271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.